SGTP-002 : A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE" for Reduction of Delayed Graft Function in Recipients of a Donation after Brain Death Kidney Transplant


Location(s): United States


Safety and efficacy study of SANGUINATE on reduction of delayed graft function (DGF) in patients who will be recipients of a donation after brain death (DBD) donor kidney.